Protein-truncating variants in BRCA2 were the most prevalent in our study (1.82%), with the founder BRCA2 c.8756delG PTV being detected in ten breast cancer cases (1.01%) which corresponds to more than half of the BRCA2 PTVs observed among cases. This evidence concerns the gene BRCA2 and breast cancer.